AFTD's newsletter emailed 6x/year for researchers that shares funding opportunities, plus research articles and updates.
FTD Research Spotlight: Genetic FTD Trials Update – Approaching a Phase 3 Milestone
The FTD research landscape is on the verge of major developments. For the first time, a Phase 3 trial has been completed for a potentially disease-modifying treatment for a type of genetic FTD, with results expected in 2025. As we wait for these Phase 3 trial results, we are taking time to summarize current updates…
FTD Research Spotlight: A New Researcher Portal and Other Updates from the FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than ever. Trials targeting sporadic FTD are also emerging, such as an ongoing trial on semantic variant primary progressive aphasia (svPPA) and an upcoming platform trial…
Celebrating 20 Years of AFTD’s Pilot Grant Program
Over the past 20 years, AFTD’s Pilot Grant program, which supports early-career researchers or new ideas, has funded $2.8 million in innovative FTD research. In 2005, AFTD founder Helen-Ann Comstock and a small group of medical advisors awarded $35,000 to Eileen Bigio, MD, a clinical researcher at Northwestern University, to identify abnormal proteins present in…
FTD Research Spotlight: Making FTD Visible by Investing in Diagnostic Biomarkers: A New Funding Opportunity
FTD researchers know the importance of identifying and validating usable biomarkers for FTD – and just how complex these tasks are. FTD-specific biomarkers could help to achieve many unmet needs for families and researchers: improved diagnostic accuracy and sensitivity, improved prognosis prediction, identification of which people suffer from which types of pathology, and accelerated drug…
Sign up to receive FTD Research Spotlight in your inbox six times a year!